Cases of Single Coronary Artery

Gadepalli, Ramesh; Gadepalli, Padma; Reddy, B. Pratap; Patel, Nilesh; Kubde, Deepak

doi:10.18410/jebmh/2019/216

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The complex and poorly understood nature of cancer pain represents a large barrier to drug development [1][2][3]6,151,152]. Available treatment options (Table 1) are symptomatic and cause significant side-effects [8,9].…”

Section: Conclusion and Future Research Directionsmentioning

confidence: 99%

Targeting TRPV1 for Cancer Pain Relief: Can It Work?

Szallasi

2024

Cancers

View full text Add to dashboard Cite

Chronic intractable pain affects a large proportion of cancer patients, especially those with metastatic bone disease. Blocking sensory afferents for cancer pain relief represents an attractive alternative to opioids and other drugs acting in the CNS in that sensory nerve blockers are not addictive and do not affect the mental state of the patient. A distinct subpopulation of sensory afferents expresses the capsaicin receptor TRPV1. Intrathecal resiniferatoxin, an ultrapotent capsaicin analog, ablates TRPV1-expressing nerve endings exposed to the cerebrospinal fluid, resulting in permanent analgesia in women with cervical cancer metastasis to the pelvic bone. High-dose capsaicin patches are effective pain killers in patients with chemotherapy-induced peripheral neuropathic pain. However, large gaps remain in our knowledge since the mechanisms by which cancer activates TRPV1 are essentially unknown. Most important, it is not clear whether or not sensory denervation mediated by TRPV1 agonists affects cancer progression. In a murine model of breast cancer, capsaicin desensitization was reported to accelerate progression. By contrast, desensitization mediated by resiniferatoxin was found to block melanoma growth. These observations imply that TRPV1 blockade for pain relief may be indicated for some cancers and contraindicated for others. In this review, we explore the current state of this field and compare the analgesic potential of TRPV1 antagonism and sensory afferent desensitization in cancer patients.

show abstract

Section: Conclusion and Future Research Directionsmentioning

confidence: 99%

Targeting TRPV1 for Cancer Pain Relief: Can It Work?

Szallasi

2024

Cancers

View full text Add to dashboard Cite

show abstract

Cases of Single Coronary Artery

Cited by 1 publication

References 9 publications

Targeting TRPV1 for Cancer Pain Relief: Can It Work?

Targeting TRPV1 for Cancer Pain Relief: Can It Work?

Contact Info

Product

Resources

About